Your Article Summary
See Latest ArticlesErlotinib Warning
JAMA, 06/29/09
Kuehn BM - The US Food and Drug Administration is alerting physicians to new safety warnings on the label of erlotinib, a drug approved for the treatment of certain patients with lung or pancreatic cancer, that warn of reports of serious gastrointestinal tract, skin, and ocular disorders in patients taking the drug.
Related Articles
Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke
Lung Cancer, 10/07/09
Relevance Score: 87%
Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines
Cancer Science, 11/16/09
Relevance Score: 85%
Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer
Journal of Clinical Oncology, 11/03/09
Relevance Score: 85%
Phase II Study of Erlotinib in Patients With Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer: SWOG S0317
Journal of Clinical Oncology, 11/12/09
Relevance Score: 83%
Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different
Anti-Cancer Drugs, 10/19/09
Relevance Score: 80%
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
Cell Therapeutics, 12/08/09
Freeze-Thaw Performance and Robustness Assessment of Celsius FFT 6L
BioPharm, 12/08/09
The Impact of Disposables on Project Economics in a New Antibody Plant
BioPharm, 12/08/09